PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
22242821-6	2012	U0126, a MEK1/2 inhibitor, prevented GO-inducible MDR-1 expression and abrogated GO resistance in HL-60/GOR cells.	U 0126	0-5	ATP binding cassette subfamily B member 1	Homo sapiens	50-55	
24510559-8	2014	P-ERK1/2 was inhibited significantly when the cells were treated with 20 mu mol/L U0126 for 48 h. The expression of NF-kappa B p65 in nuclear and P-gp were also down-regulated.	U 0126	82-87	ATP binding cassette subfamily B member 1	Homo sapiens	146-150	
26293643-7	2016	Moreover, UCH-L1-overexpressing clones treated with U0126 (an Erk1/2-specific inhibitor) significantly decreased the expression of MDR1, CD147, MMP2, and MMP9.	U 0126	52-57	ATP binding cassette subfamily B member 1	Homo sapiens	131-135	
19093255-6	2008	Treatment of tumor cells with U-0126, an inhibitor of MAPK/Erk, also down-regulated MMP11 and MDR1 expression.	U 0126	30-36	ATP binding cassette subfamily B member 1	Homo sapiens	94-98	
22678786-6	2012	P-ERK1/2 and P-gp were apparently down-regulated by U0126 at the concentrations of 20 mumol/L, 40 mumol/L and 60 mumol/L.	U 0126	52-57	ATP binding cassette subfamily B member 1	Homo sapiens	13-17	
21159167-4	2010	RESULTS: U0126 significantly modulated endogenous expression of several important drug resistance (BCL2, ABCB1, ABCC3), prosurvival (BCL2), DNA repair (BRCA1, BRCA2), hormone receptor (AR, ESR2, PPARgamma) and drug metabolism (CYP3A4) genes newly identified in MM cells.	U 0126	9-14	ATP binding cassette subfamily B member 1	Homo sapiens	105-110	
17620438-5	2007	We further found that U0126 down-regulated exogenous P-gp expression in the MDR1-transduced human breast cancer cells, MCF-7/MDR and MDA-MB-231/MDR.	U 0126	22-27	ATP binding cassette subfamily B member 1	Homo sapiens	53-57	
17620438-5	2007	We further found that U0126 down-regulated exogenous P-gp expression in the MDR1-transduced human breast cancer cells, MCF-7/MDR and MDA-MB-231/MDR.	U 0126	22-27	ATP binding cassette subfamily B member 1	Homo sapiens	76-80	
17620438-9	2007	Pulse-chase analysis revealed that U0126 promoted P-gp degradation but did not affect the biosynthesis of this gene product.	U 0126	35-40	ATP binding cassette subfamily B member 1	Homo sapiens	50-54	
17953842-7	2007	After being treated by U0126 for 12 h, the expressions of mdr1, MRP1, LRP genes and protein in those cells were decreased to some extent.	U 0126	23-28	ATP binding cassette subfamily B member 1	Homo sapiens	58-62	
15526378-14	2004	Compared with controls, a significant decrease in MDR-1 mRNA (53.3%), MRP-1 mRNA (59.7%) as well as LRP mRNA (56.4%) was observed in the U0126 treated transfected cells after 12 h. Western blot also demonstrated that the protein expression of these MDR associated genes slightly reduced after treated with U0126 for 12 h (MDR-1 40.1%, MRP-1 29.4%, LRP35.7%).	U 0126	137-142	ATP binding cassette subfamily B member 1	Homo sapiens	322-327	
17441962-5	2007	Moreover, Erk1/2 in CD147-overexpressing clones were observed to be highly activate and after treatment with U0126, an Erk1/2-specific inhibitor, the expression of MDR1, MMP2 and MMP9 were decreased significantly.	U 0126	109-114	ATP binding cassette subfamily B member 1	Homo sapiens	164-168	
15526378-14	2004	Compared with controls, a significant decrease in MDR-1 mRNA (53.3%), MRP-1 mRNA (59.7%) as well as LRP mRNA (56.4%) was observed in the U0126 treated transfected cells after 12 h. Western blot also demonstrated that the protein expression of these MDR associated genes slightly reduced after treated with U0126 for 12 h (MDR-1 40.1%, MRP-1 29.4%, LRP35.7%).	U 0126	137-142	ATP binding cassette subfamily B member 1	Homo sapiens	50-55	
15389514-10	2005	In contrast the JNK inhibitor SP600125 and the ERK1,2 inhibitor UO126 resulted in increase of HIF-1alpha and P-glycoprotein in the control as well as the hyperthermia-treated samples, indicating negative regulation of intrinsic HIF-1alpha and P-glycoprotein expression by ERK1,2 and JNK signaling cascades.	U 0126	64-69	ATP binding cassette subfamily B member 1	Homo sapiens	109-123	
15389514-10	2005	In contrast the JNK inhibitor SP600125 and the ERK1,2 inhibitor UO126 resulted in increase of HIF-1alpha and P-glycoprotein in the control as well as the hyperthermia-treated samples, indicating negative regulation of intrinsic HIF-1alpha and P-glycoprotein expression by ERK1,2 and JNK signaling cascades.	U 0126	64-69	ATP binding cassette subfamily B member 1	Homo sapiens	243-257	
29061787-9	2017	The DOX-induced P-gp overexpression was partially suppressed by an inhibitor of MEK1/2 (U0126), but not by a PI3K inhibitor (LY294002).	U 0126	88-93	ATP binding cassette subfamily B member 1	Homo sapiens	16-20	
29061787-10	2017	Interestingly, the expression of P-gp was synergistically inhibited by combined treatment of U0126 with LY294002 and also inhibited by an mTORC1 inhibitor, rapamycin.	U 0126	93-98	ATP binding cassette subfamily B member 1	Homo sapiens	33-37	
28928846-4	2017	The reverse transcription-quantitative polymerase chain reaction (RT-qPCR) was used to determine P-glycoprotein (P-gp) and multidrug resistance-associated protein 1 (MRP1) mRNA expression following treatment with various concentrations of U0126.	U 0126	239-244	ATP binding cassette subfamily B member 1	Homo sapiens	97-111	
28928846-4	2017	The reverse transcription-quantitative polymerase chain reaction (RT-qPCR) was used to determine P-glycoprotein (P-gp) and multidrug resistance-associated protein 1 (MRP1) mRNA expression following treatment with various concentrations of U0126.	U 0126	239-244	ATP binding cassette subfamily B member 1	Homo sapiens	113-117	
28928846-11	2017	The results of the present study indicate that the MEK inhibitor U0126 enhances sensitivity to chemotherapeutic drugs by downregulating P-gp and MRP1 expression in resistant hepatocellular carcinoma cells.	U 0126	65-70	ATP binding cassette subfamily B member 1	Homo sapiens	136-140	
28314481-11	2017	Moreover, MAPK inhibitors including U0126 (an ERK1/2/MAPK inhibitor) and SB202190 (p38/MAPK inhibitor) suppressed an increase of MDR1 mRNA levels in the cells treated with benzophenones (GK, OC) and xanthone ISO, respectively.	U 0126	36-41	ATP binding cassette subfamily B member 1	Homo sapiens	129-133	
11562428-9	2001	Furthermore, PD-98059 and U0126, two MAPK inhibitors, blocked PLC-gamma 1-induced expression of MDR1.	U 0126	26-31	ATP binding cassette subfamily B member 1	Homo sapiens	96-100	
31770110-7	2020	Stress-induced up regulation of ABCB1 was mitigated by combined use of pharmacologic inhibitors U0126 and ISRIB, which inhibit stress signalling and have potential for use as adjuvants to enhance the activity of ABCB1 inhibitors.	U 0126	96-101	ATP binding cassette subfamily B member 1	Homo sapiens	32-37	
31770110-7	2020	Stress-induced up regulation of ABCB1 was mitigated by combined use of pharmacologic inhibitors U0126 and ISRIB, which inhibit stress signalling and have potential for use as adjuvants to enhance the activity of ABCB1 inhibitors.	U 0126	96-101	ATP binding cassette subfamily B member 1	Homo sapiens	212-217	
31312250-13	2019	Treatment of HeLa/DDP cells transfected with P16 plasmid with ERK-specific inhibitor U0126 significantly decreased the expression of pERK1/2 and increased the expression of P-gp from 6 h to 48 h. Moreover, after 72 h, the expression of pERK1/2 was up-regulated and the expression of P-gp was inhibited.	U 0126	85-90	ATP binding cassette subfamily B member 1	Homo sapiens	173-177	
31312250-13	2019	Treatment of HeLa/DDP cells transfected with P16 plasmid with ERK-specific inhibitor U0126 significantly decreased the expression of pERK1/2 and increased the expression of P-gp from 6 h to 48 h. Moreover, after 72 h, the expression of pERK1/2 was up-regulated and the expression of P-gp was inhibited.	U 0126	85-90	ATP binding cassette subfamily B member 1	Homo sapiens	283-287